Literature DB >> 8088716

Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study.

C Schmid1, P G Isaacson.   

Abstract

Proliferation centres, also known as pseudofollicles, are present in approximately 90% of lymphocytic lymphomas (B-CLL). They consist of loosely arranged larger cells that often contain prominent nucleoli. In contrast to true B-cell follicles, which may be found entrapped within the small lymphocytic infiltrate in sections of B-CLL, proliferation centres are said not to contain follicular dendritic cells, although their presence has been occasionally recorded. We have carried out an immunohistochemical study of proliferation centres from 30 lymph node specimens of known cases of B-CLL, classified according to the Kiel classification, in six of which fresh frozen in addition to paraffin embedded tissue was available. We have compared proliferation centres with the surrounding small lymphocytic infiltrate and reactive B-cell follicles with respect to the presence of follicular dendritic cells and their associated network of IgM and complement, the cell proliferation fraction, the concentration of T-cells and the expression of bcl-2 protein. Most proliferation centres contained a delicate follicular dendritic cell network which was associated with IgM and complement, and showed a higher proliferation fraction than the surrounding small lymphocytic infiltrate. The proliferation centres contained more T-cells than the surrounding infiltrate and showed decreased expression of bcl-2 protein. Entrapped reactive B-cell follicles contained a much denser network of follicular dendritic cells, associated with much stronger expression of IgM and complement, and exhibited a very high proliferation fraction; they contained many T-cells and expressed very little bcl-2 protein.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8088716     DOI: 10.1111/j.1365-2559.1994.tb00553.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  33 in total

1.  Histological and immunoglobulin VH gene analysis of interfollicular small lymphocytic lymphoma provides evidence for two types.

Authors:  D W Bahler; N S Aguilera; C C Chen; S L Abbondanzo; S H Swerdlow
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells.

Authors:  Shaun Willimott; Simon D Wagner
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

3.  Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.

Authors:  Eva Giné; Antoni Martinez; Neus Villamor; Armando López-Guillermo; Mireia Camos; Daniel Martinez; Jordi Esteve; Xavier Calvo; Ana Muntañola; Pau Abrisqueta; Maria Rozman; Ciril Rozman; Francesc Bosch; Elias Campo; Emili Montserrat
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

4.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

5.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

6.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

Review 7.  Growth and survival of B-chronic lymphocytic leukaemia cells.

Authors:  O Söderberg
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

Review 8.  Molecular pathology of low grade malignant lymphomas.

Authors:  H Ratech
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

9.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Authors:  Davide Bagnara; Matthew S Kaufman; Carlo Calissano; Sonia Marsilio; Piers E M Patten; Rita Simone; Philip Chum; Xiao-Jie Yan; Steven L Allen; Jonathan E Kolitz; Sivasubramanian Baskar; Christoph Rader; Hakan Mellstedt; Hodjattallah Rabbani; Annette Lee; Peter K Gregersen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

10.  Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.

Authors:  Silvia Mele; Stephen Devereux; Andrea G Pepper; Elvira Infante; Anne J Ridley
Journal:  Blood Adv       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.